Trials / Completed
CompletedNCT06881264
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 With Insulin Glargine in Chines Subjects With Type 2 Diabetes Inadequately Controlled With Metformin in Combination With or Without Another Oral Antidiabetic Drug (OAD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 401 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR17031 injection | HR17031 injection |
| DRUG | insulin glargine | insulin glargine |
Timeline
- Start date
- 2024-04-30
- Primary completion
- 2025-09-19
- Completion
- 2025-09-19
- First posted
- 2025-03-18
- Last updated
- 2026-01-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06881264. Inclusion in this directory is not an endorsement.